Used in active specific immunotherapy for the treatment of cancer, particularly lung cancer. It induces an immune response against GM3 gangliosides, which are overexpressed on the surface of certain tumor cells. By targeting these tumor-associated antigens, it helps the immune system recognize and destroy cancer cells. Racotumomab has been investigated in clinical trials as a therapeutic vaccine, showing potential to improve survival in patients with advanced non-small cell lung cancer. It is typically administered via injection and works by stimulating the production of anti-idiotypic antibodies that mimic GM3, leading to a sustained immune response.